



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison

Donald R. Banowitz
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaston
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblentz
James J. Pohl
John T. Haran

Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier*
Shameek Ghose
Randall K. Baldwin
Daniel J. Nevriy
Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Mita Mukherjee
Scott M. Woodhouse
Peter A. Socarras

Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

November 16, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8684
INTERNET ADDRESS:
DLETTING@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1646

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 10/535,458; Filed: November 20, 2003
For: **Novel Gene Targets and Ligands That Bind Thereto for Treatment
and Diagnosis of Colon Carcinomas**
Inventors: MCLACHLAN *et al.*
Our Ref: 2159.0640005/EKS/PAC/DLL

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF Cover Letter;
2. Information Disclosure Statement;
3. 5 sheets of IDS Forms (PTO/SB/08A/B) listing the cited documents (FP1 and NPL1-NPL31);
4. Copies of the cited documents (FP1 and NPL1-NPL31); and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
November 16, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Danielle L. Letting", with a long horizontal flourish extending to the right.

Danielle L. Letting
Agent for Applicants
Registration No. 56,971

PAC/DLL/bls
Enclosures

729144_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MCLACHLAN *et al.*

Appl. No.: 10/535,458

(U.S. Nat'l Phase of Int'l Appl.
No. PCT/US03/37206)

Int'l Filing date: November 20, 2003

For: **Novel Gene Targets and Ligands
that Bind Thereto for Treatment
and Diagnosis of Colon
Carcinomas**

Confirmation No.: 1633

Art Unit: 1646

Examiner: *To Be Assigned*

Atty. Docket: 2159.0640005/EKS/PAC/DLL

**Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents, **FP1** and **NPL1** to **NPL31**, are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of U.S. patent, cited on the attached Form PTO/SB/08A as document **US1**, is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Danielle L. Letting
Agent for Applicants
Registration No. 56,971

Date: 11.16.2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

625803v1